Israel Englander Viracta Therapeutics, Inc. Transaction History

Millennium Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.89 - $2.13 $80,769 - $193,301	-90,752 Reduced 62.44%	54,595 $76,000
Q1 2023 May 15, 2023	SELL	$1.38 - $2.29 $73,908 - $122,645	-53,557 Reduced 26.93%	145,347 $231,000
Q4 2022 Feb 14, 2023	BUY	$1.26 - $4.38 $61,147 - $212,561	48,530 Added 32.27%	198,904 $290,000
Q3 2022 Nov 14, 2022	SELL	$3.32 - $5.69 $550,904 - $944,170	-165,935 Reduced 52.46%	150,374 $642,000

9.39M

5.9K

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $18.4M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.